APL 1501
Alternative Names: APL-1301; APL-1501Latest Information Update: 28 Feb 2026
At a glance
- Originator Asieris Pharmaceuticals
- Class Antibacterials; Antineoplastics; Urinary anti-infective agents
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bladder cancer; Solid tumours; Urinary tract infections; Urogenital cancer
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for phase-I development in Urinary-tract-infections in Australia (PO)
- 31 Jan 2025 Syneos Health terminates phase I trial in for Healthy volunteers in Australia due to a business decision and development strategy (PO, Tablet) (NCT06435039)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (PO, Controlled release)